Avaí Bio and Austrianova Encapsulated Klotho-Producing Cells
The companies have successfully utilized GMP-quality cells to initiate a sustainable alpha-Klotho production and delivery program.
Updated on Sept. 30, 2026 in Biotech
Live Poll
Should medical advances in longevity protein research be prioritized for broad healthcare development?
Avaí Bio and Austrianova have successfully encapsulated Klotho-producing cells using Cell-in-a-Box technology. This research-stage development establishes a method to contain cells while enabling the steady release of therapeutic alpha-Klotho protein.
Why it matters
This partnership aims to solve the challenge of sustainable production and targeted delivery of alpha-Klotho, a protein associated with significant physiological processes. By standardizing cell manufacturing, the program seeks to transition therapeutic protein delivery from experimental to scalable.
The researchers utilized a GMP (Good Manufacturing Practice) Master Cell Bank to generate a Working Cell Bank for the encapsulation process. The resulting capsule membrane ensures permanent cell containment while allowing the therapeutic Klotho protein to diffuse into the surrounding media.
The players
Avaí Bio
A biotechnology firm focused on developing scalable delivery platforms for therapeutic proteins.
Austrianova
A Singapore-based company that specializes in Cell-in-a-Box microencapsulation technology for clinical cell therapy.
The details
The companies used Cell-in-a-Box technology — a cellulose-based capsule system that protects cells from the host immune system while enabling the diffusion of secreted therapeutic proteins. By banking the Klotho-producing cells under GMP standards — manufacturing protocols required for human-grade therapies — the researchers ensured that the source biological material is consistent and scalable for future testing.
Timeline
September 30, 2026: The companies announced the successful encapsulation of the cell lines.
The Tech Race
This development marks a new phase in the development of alpha-Klotho protein therapeutics by shifting from traditional protein infusion models to cellular production platforms. It follows a competitive industry pattern of using specialized microencapsulation to overcome the instability of therapeutic proteins in vivo.
This development is currently in the research phase and does not yet affect clinical treatment or patient access. Future performance benchmarks will determine whether this method can be optimized for long-term production and eventually move toward human study protocols.
The takeaway
The success of this encapsulation milestone provides a foundation for more complex optimization studies regarding cell growth and long-term secretion stability. Watch for upcoming announcements regarding capsule expansion studies that will test the viability of these cells for sustained therapeutic use.
Further reading
For broader context on cellular production methods, explore our Biotech section.
More information
For additional information on the partnership, visit the Avaí Bio company information page.
Live Poll
Should medical advances in longevity protein research be prioritized for broad healthcare development?
